ShiSi Pharmaceutical Group: Approval granted for the production registration of Propofol Hydrochloride Injection.

On January 30, at noon, Shisanyao Group announced on the Hong Kong Stock Exchange that the group has obtained the drug production registration approval from the China National Medical Products Administration for the Propafenone Hydrochloride Injection, which belongs to the third category of chemical drugs and has been approved through consistency evaluation, making it the third domestic enterprise to receive such approval. The Propafenone Hydrochloride Injection is mainly used to treat supraventricular tachycardia, such as atrioventricular nodal reentrant tachycardia, WPW syndrome with supraventricular tachycardia or paroxysmal atrial fibrillation, and ventricular tachycardia that requires treatment or is life-threatening.